ERES East Resources Acquisition Company

Emerging International Pharmaceutical Enterprise Signs Agreements with eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Awards Total Approximately $2.2 million and Include Digital Collection, Interpretation, and Distribution of Cardiac Safety Data PHILADELPHIA, Dec. 8 /PRNewswire/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has received agreements for approximately $2.2 million in cardiac safety monitoring and services from an emerging international pharmaceutical organization for one of its drug candidates in late phase development. The agreements cover a Phase III study that will be conducted at 186 research sites on three continents and retrospective analysis of ECGs that were collected during a previous study for the same compound. eRT will provide comprehensive site support and 186 units of 12-lead ECG recording equipment, which is designed to facilitate the collection of cardiac safety data that are subsequently provided to eRT for analysis. eRT will manage collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "These exciting awards are indicative of two related key trends in today's market for ECG core laboratory services," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "The Phase III study, which includes 186 sites on three continents, exemplifies the type of massively distributed later phase studies being driven by regulatory guidance. These trials require a cardiac safety partner with the infrastructure to provide logistics and site support services across a far-flung investigator network. The retrospective award represents a continuing trend among sponsors to centralize analysis of cardiac safety data collected during previous studies to strengthen compliance with the emerging guidance." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473; Matt Hayden of Hayden Communications, +1-760-487-1137, for eResearchTechnology, Inc. Web site: http://www.ert.com/

Copyright